

Express Mail No. EB 132601931 US  
Attorney Docket No. 017092-0046-999  
CAM 011104-999015

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                 |  |                      |                  |
|-----------------|--|----------------------|------------------|
| Application of: | Wu, et al.   | Confirmation No.:    | 3434             |
| Serial No.:     | 10/781,442   | Art Unit:            | 1626             |
| Filed:          | February 18, 2004  | Examiner:            | Grazier, Nyeemah |
| For:            | Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists | Attorney Docket No.: | 017092-0046-999  |

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT IN REPLY TO ACTION OF DECEMBER 13, 2006**

Sir:

In response to the Office Action mailed December 13, 2006, Applicants request entry of this Amendment into the file of the above-identified application and consideration of the remarks below.

Submitted concurrently herewith are:

- (A) A Petition for Extension of Time for three (3) Months;
- (B) A supplemental information disclosure statement along with a list of references;
- (C) An unexecuted Declaration of Robert Market under 37 CFR 1.132 (An executed Declaration will be provided under separate cover.);
- (D) A Petition For Correction of Inventorship Under 37 C.F.R. §1.48(a);
- (E) A Consent of Assignee to Change Inventorship Under 37 C.F.R. §1.48(a) and Statement Under 37 C.F.R. § 3.73(b);
- (F) Statements from Inventors (5) in Support of Petition for Correction of Inventorship; and
- (G) Declarations from Correct Inventors

**Amendments to the Inventors** begins on page 2 of this paper,

**Complete listing of claims** beginning on page 3;

**Remarks** beginning on page 6.